Posts Tagged ‘Eisai’
Hopes and Questions raised by Alzheimer’s drug Leqembi (lecanemab)
The FDA has approved Leqembi, the first disease-modifying treatment for early-stage Alzheimer’s and a precursor condition, mild cognitive impairment. Medicare has said it will pay for the therapy. Medical centers across the country are scrambling to finalize policies and procedures for providing the medication to patients, possibly by summer’s end or early autumn. It’s a…
Read MoreGrowing controversy over role of FDA and Medicare in promoting anti-amyloid drugs given limited benefit, high cost, severe side-effects
The War Over Whether Medicare Should Pay For The New Anti-Alzheimer’s Drugs (Forbes): The powerful Alzheimer’s Disease lobby is fighting a multi-billion-dollar battle on two fronts. It is quietly trying to limit restrictions the Food and Drug Administration puts on the use of new drugs aimed at slowing the progression of the brain disease. And…
Read MoreNews on how the brain changes over time, how to clear foggy brains, how to multitask (or not), and more
Welcome to a new edition of SharpBrains’ e‑newsletter, featuring timely brain & mental health news and a fun brain teaser to test the limits of multi-tasking. #1. Collaborative neuroimaging initiative BrainChart helps chart how brains change across the lifespan. Among the many fascinating findings: “The volume of grey matter (brain cells) increases rapidly from mid-gestation…
Read MoreGeisinger and Eisai to test real-world validity of AI-powered Passive Digital Marker (PDM) in detecting early cognitive impairment and dementia
Research collaboration will test novel algorithm’s effectiveness on Geisinger data (press release): Geisinger and Eisai Inc. today announced a collaborative effort to study the potential effectiveness of an artificial intelligence (AI) tool in the detection of cognitive impairment that could identify dementias, including Alzheimer’s disease (AD). If effective, the AI tool could potentially be developed…
Read More